Eas­ing joint pain

The Star Malaysia - Star2 - - BODY, MIND & SOUL -

OS­TEOARTHRI­TIS is a de­gen­er­a­tive joint dis­or­der and it is found that about up to 20% of Malaysian adults in the pop­u­la­tion are prone to this disease, with 40% above the age of 65 af­fected.

In peo­ple af­fected by os­teoarthri­tis, the car­ti­lage (con­nec­tive tis­sue) be­tween their bones grad­u­ally wastes away, lead­ing to painful rub­bing of bone on bone in the joints.

With­out the car­ti­lage, joints are un­able to ab­sorb shock and im­pact and thus af­fect­ing the pa­tient’s move­ment al­to­gether.

With os­teoarthri­tis sim­ple ev­ery­day move­ments such as tak­ing the stairs, walk­ing or car­ry­ing things can be dif­fi­cult.

Treat­ment op­tions for os­teoarthri­tis range from oral med­i­ca­tions, in­jec­tions and sup­ple­ments, to life­style changes. Many of th­ese treat­ments come with dis­ad­van­tages.

While glu­cosamine and chon­droitin have been widely used, for many, ad­e­quate con­trol of joint pain af­ter many years of use has led them to won­der whether any sig­nif­i­cant relief can be achieved with fur­ther use.

Both glu­cosamine and chon­droitin are nat­u­ral sub­stances found in car­ti­lage. Glu­cosamine is an amino su­gar that may help re­new car­ti­lage and chon­droitin sul­fate is a com­plex car­bo­hy­drate that is thought to help car­ti­lage re­tain wa­ter. Os­teoarthri­tis causes pain, swelling and stiff­ness in joints and dam­ages car­ti­lage over time.

So, it is be­lieved that ex­tra glu­cosamine and chon­droitin can help main­tain and per­haps re­pair the dam­age caused by this wear and tear of the joints.

In or­der to as­sess just how ef­fec­tive glu­cosamine and chon­droitin are, the US Na­tional In­sti­tutes of Health funded a US$12.5mil ran­domised clin­i­cal trial.

It as­signed 1,583 peo­ple to take ei­ther glu­cosamine, chon­droitin, a com­bi­na­tion of the two, an an­ti­in­flam­ma­tory drug (cele­coxib) or a placebo (a “dummy” pill).

Nei­ther the par­tic­i­pants nor the re­searchers knew what they were tak­ing.

The re­sults were in­deed a sur­prise. The ma­jor­ity of pa­tients re­ported no sig­nif­i­cant dif­fer­ence in pain relief be­tween glu­cosamine, chon­droitin, a com­bi­na­tion of the two and the placebo.

Over­all, 60% of pa­tients tak­ing the placebo said their pain was re­duced by about 20%, while 66% of those tak­ing the sup­ple­ments re­ported sim­i­lar pain re­duc­tion.

The re­sults were pub­lished in 2006 in the New Eng­land Jour­nal of Medicine.

Re­cently, Pro Bono Bio, the global leader in nano-phys­i­cal health care prod­ucts, an­nounced the UK Char­ity launch of Flexiseq.

Pro Bono Bio chair­man and chief ex­ec­u­tive John Mayo said: “I am proud to bring the world’s first clin­i­cally proven nano-phys­i­cal prod­uct for pain relief to the UK. For the UK Char­ity launch pe­riod, Flexiseq is ex­clu­sively avail­able online via the Arthri­tis Re­search UK web­site www. arthri­tis­re­searchUK.org/Flexiseq and in se­lected phar­ma­cies.

This char­ity launch is a unique way for us to con­trib­ute to medi- cal re­search by sup­ply­ing Arthri­tis Re­search UK at a spe­cial price which al­lows them to sell to the pub­lic at a re­duced price and gen­er­ate funds for the char­ity.”

Flexiseq’s proven ef­fi­cacy comes with sig­nif­i­cant ad­van­tages as the prod­uct has no con­tra-indi­ca­tions and does not con­tain drugs so it can­not cause drug-to-drug in­ter­ac­tions. With over six mil­lion doses ad­min­is­tered since its launch, there have been no re­ported sys­temic side ef­fects.

Flexiseq was launched in Malaysia in 2012, the sec­ond coun­try world­wide to have the prod­uct avail­able to joint pain suf­fer­ers.

Since its launch, thou­sands of Malaysians have ben­e­fited from Flexiseq ahead of other coun­tries such as the UK and Amer­ica. Flexiseq is al­ready suc­cess­fully sold in Ger­many, Ire­land and Sin­ga­pore. Last year, it won the In­no­va­tion Award 2013 from the Fed­eral As­so­ci­a­tion of Ger­man Phar­ma­cists.

In Ire­land, Flexiseq has be­come the fastest grow­ing over-the-counter prod­uct that phar­ma­cies there have seen in re­cent times.

Mode of ac­tion

Flexiseq is dif­fer­ent as it does not con­tain an ac­tive phar­ma­ceu­ti­cal in­gre­di­ent but works through a patented phys­i­cal mode of ac­tion be­cause it in­creases the level of bi­ol­u­bri­ca­tion in the af­fected joint.

One of the fea­tures of os­teoarthri­tis is a de­ple­tion in the level of phos­pho­lipids in the joint, nor­mally found in the liq­uid around the car­ti­lage. Flexiseq con­tains patented phos­pho­lipid vesi­cles that are for­mu­lated us­ing Se­ques­some Tech­nol­ogy to be ul­tra-de­formable.

It has been shown to pen­e­trate into the joint, af­ter top­i­cal ap­pli­ca­tion and be­ing al­lowed to dry, where it sup­ple­ments the bio-lu­bri­ca­tion in the syn­ovial space.

Pro Bono Bio chief op­er­at­ing of­fi­cer Michael Earl said, “The proven phys­i­cal mode of ac­tion and the lack of an ac­tive phar­ma­ceu­ti­cal in­gre­di­ent give Flexiseq the best of both worlds: it works and it’s safe. The lack of sys­temic side ef­fects that have been recorded when drugs are used chron­i­cally, such as gas­troin­testi­nal bleed­ing, kid­ney fail­ure, heart at­tack and stroke, to­gether with a lack of drug in­ter­ac­tions make Flexiseq a par­tic­u­larly suit­able op­tion for many os­teoarthri­tis pa­tients.

“The pa­tients are el­derly and may be suf­fer­ing from other con­di­tions and tak­ing other med­i­ca­tions, which com­pli­cate the choice of ther­apy for their painful joints.”

In Malaysia, thou­sands have been given a new free­dom of joint move­ment which has im­proved the qual­ity of their lives. An al­ter­na­tive such as Flexiseq has en­abled them to avoid oral med­i­ca­tions, with some pa­tients be­ing able to stop oral painkillers com­pletely.

Also, be­ing able to avoid in­jec­tions, which can be costly and painful, has been much wel­comed.

For oth­ers, to be able to walk again af­ter ap­ply­ing a sim­ple gel like Flexiseq over as short a pe­riod as six weeks, has been an im­mense relief and joy.

For more in­for­ma­tion visit www.flexiseq.com.my

Last year, Flexiseq won the In­no­va­tion Award 2013 from the Fed­eral As­so­ci­a­tion of Ger­man Phar­ma­cists.

Newspapers in English

Newspapers from Malaysia

© PressReader. All rights reserved.